Lilly turns to Amylin
Executive Summary
Lilly will collaborate with Amylin on the development of AC2993 for type 2 diabetes, following Lilly's decision not to pursue Phase III studies of its in-house glucagon-like peptide-1 analogue. Lilly opted not to proceed to Phase III with its drug because of a technical failure in the formulation that caused adverse effects at the injection site, company says. AC2993 has a similar mechanism of action and is in Phase III; the companies hope to file an NDA in 2004. Agreement calls for Lilly to make an $80 mil. upfront payment and purchase $30 mil. in equity. Amylin will receive up to $215 mil. in additional milestone payments, and companies will split U.S. profits equally. Amylin previously worked with Johnson & Johnson on the development of Symlin (pramlintide), but J&J withdrew from the agreement...
You may also be interested in...
Amylin Exenatide NDA Filing Expected Mid-2004; Symlin Launch in Q1
Amylin is eyeing a mid-2004 filing date for its exenatide NDA
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.